Local communities, businesses, charities and other groups need to come together in a 'national movement' in order to tackle the …
Immunisation against S. aureus has potential in selected target groups Staphylococcus aureus bacteria have become a key concern in both …
Novartis has surpassed estimates for its second quarter performance, boosted by higher than expected sales of its flagship cardiovascular and …
AstraZeneca is training staff in a new Code of Conduct that aims to ensure employees at all levels and locations …
Dining out, staff training and medical education are among the major issues under the microscope in the US industry association …
GlaxoSmithKline has joined forces with Swiss biopharmaceutical company Actelion to bring a new insomnia treatment to market.The deal could be …
After more than a year of uncertainty and months of tense negotiation, the ABPI looks to have secured a very …
Aisling Burnand, chief executive of the biotech representative body the BIA welcomed the deal, saying she was pleased the "months …
Agreement has been reached on a new UK medicines pricing deal which safeguards the industry's ability to set its own …
Roche has been suspended from the ABPI for at least six months after being found guilty of bringing discredit on …
Over recent years the pharmaceutical industry has been unable to escape the mantra of return on investment (ROI). Investment in …
What, in your opinion, is the current state of marketing in pharma? What a question. How do you measure the …
Regulatory warning for anti-epileptic drugs presents greatest threat to non-epilepsy indicationsThe FDA is close to adding a black box warning …
Pharmaceutical marketers across Europe have a new set of rules to follow if they want to work with patient groups. …
No-one in pharmaceuticals or the NHS needs to be told their world is changing dramatically. The proof is all around, …
UK doctors have voted in favour of allowing patients to pay privately for treatments unavailable on the NHS, but continuing …
GlaxoSmithKline's Tyverb is the latest high-cost cancer treatment to be rejected by the medicines watchdog NICE. Using the breast cancer …